What is REGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 95.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for REGN?

P/E (TTM) is 19.15 and 52-week range is $572.75 to $859.34 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s REGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for REGN?

The company profile lists revenue (TTM) near $15.09B, net income (TTM) near $4.20B, EPS (TTM) near $40.45 when available from the market-data feed. Figures are informational and may lag live markets.

Does REGN show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $3.61, yield near 0.46%, ex-dividend date Aug 18, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Regeneron Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Tarrytown, New York, US, 103M shares outstanding, ISIN US75886F1075 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Regeneron Pharmaceuticals, Inc.

$REGN

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Employees

15,410

Website

www.regeneron.com/

IPO

1991-04-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US75886F1075

Headquarters

Tarrytown, New York, US

Shares outstanding

103M

NAICS sector

Manufacturing

Institutional ownership

93.59%

Browse other companiesFree AI scores and summaries for more stocks